FDA intervenes to prevent neonatal nutrition supply crisis amid outsourcing facility shutdowns

The US Food and Drug Administration has implemented temporary measures to secure access to critical neonatal parenteral nutrition amid potential supply disruptions caused by the closure of outsourcing facilities, ensuring vulnerable newborns continue to receive lifesaving nutrients.

The US Food and Drug Administration has moved to protect access to neonatal starter parenteral nutrition, the intravenous nutrient mixtures used for premature and critically ill newborn babies who cannot yet feed by mouth or through a tube. The agency said it acted after children’s hospitals warned of a possible supply shortfall linked to the shutdown of two outsourcing facilities that made standardised versions of the products.

According to the FDA, the temporary measure is meant to prevent interruptions while longer-term supply arrangements are worked out. Acting Commissioner Kyle Diamantas said the agency was prepared to use “every regulatory tool available” to avoid gaps in care, while Michael Davis, acting director of the agency’s drug centre, said the nutrition is especially important in the first days after birth for babies who are most medically fragile.

The response takes the form of immediately effective guidance on compounding, the pharmacy process used to prepare customised medicines. In practical terms, the FDA is setting out temporary enforcement priorities for certain state-licensed pharmacies, federal facilities and outsourcing facilities that make starter parenteral nutrition under federal drug law. The agency says it will keep tracking demand and may take further steps if the situation worsens.

The action also reflects a broader concern in neonatal care: these products are specialised, time-sensitive and difficult to replace quickly if a supplier exits the market. By allowing temporary flexibility, the FDA is trying to give hospitals a bridge until a more stable supply chain is in place.